Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Important clues to prevention and management of delirium are being ignored

Important clues to the prevention and management of delirium, a condition affecting an estimated 7 million hospitalized Americans, are being ignored, according to a study from the Regenstrief Institute and the Indiana University School of Medicine.

18 Nov 2011

UK to offer master's degree in music therapy

The University of Kentucky will be the first higher education institution in the Commonwealth of Kentucky to offer a graduate degree in music therapy. The program, housed at the UK School of Music, was officially approved by the state's Council on Postsecondary Education earlier in November and will start accepting graduate students in the spring of 2012.

18 Nov 2011

New protein in the fruit fly eye may shed light on neurodegenerative diseases

Researchers at the University of Wisconsin-Madison and collaborators have discovered a powerful new protein in the eye of the fruit fly that may shed light on blinding diseases and other sensory problems in humans.

18 Nov 2011

New framework to improve care for patients with delirium

A new national plan of action provides a roadmap for improving the care of patients with delirium, a poorly understood and often unrecognized brain condition that affects approximately seven million hospitalized Americans each year.

18 Nov 2011

Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial

The drug, ladostigil, is a molecule that combines components from the existing drugs Azilect and Exelon. Teva's Azilect, for the treatment of Parkinson's disease, was developed by Prof. Emeritus Moussa Youdim of the Technion-Israel Institute of Technology. Azilect is the only anti-Parkinson's drug that has proven to have a disease-modifying effect. Novartis's Exelon was developed by Prof. Marta Weinstock-Rosin of Hebrew University to treat Alzheimer's disease.

17 Nov 2011

People with prior stroke or diabetes benefit from thrombolytic therapy

People with a history of stroke or diabetes who were given clot-busting drugs to break up blood clots after stroke fared better than those who did not receive the drugs, according to a study published in the November 16, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

17 Nov 2011

Excessive vitamin D levels can lead to onset of AF

While previous studies have linked vitamin D deficiency to an increased risk for cardiovascular disease, new research at the Intermountain Medical Center Heart Institute shows that too much vitamin D can lead to the onset of a dangerous heart condition known as atrial fibrillation.

16 Nov 2011

AHA honors Gladstone senior investigator with Distinguished Scientist Award

The American Heart Association will today present Gladstone Institutes Senior Investigator and President Emeritus Robert Mahley, MD, PhD, with the 2011 AHA Distinguished Scientist Award, bestowing yet another honor on one of Gladstone's founding cardiovascular scientists.

16 Nov 2011

TU Darmstadt chemists develop new method to diagnose Alzheimer's

Chemists at the Technische Universität Darmstadt have developed a new method for diagnosing Alzheimer's disease. The method involves making protein deposits on mucous nasal membranes that are detectable years before the disease erupts visible.

16 Nov 2011

Nearly one-fifth of Americans have severe hearing loss

Nearly a fifth of all Americans 12 years or older have hearing loss so severe that it may make communication difficult, according to a new study led by Johns Hopkins researchers and published in the Nov. 14 Archives of Internal Medicine.

15 Nov 2011

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that it has participated in a U.S. $3 million financing round of Avraham Pharmaceuticals Ltd. together with Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and others.

14 Nov 2011

Top-line results from Probiodrug's PQ912 Phase 1 SAD, MAD study for Alzheimer's disease

Probiodrug AG, a biotech company developing products for the treatment of neurodegenerative and inflammatory diseases, with a particular focus on Alzheimer's disease (AD), today announced top-line results of its Phase 1 single (SAD) and multiple ascending dose (MAD) study of PQ912 in healthy volunteers.

14 Nov 2011

New insight into how the human brain learns and remembers

New research released today provides insight into one of neuroscience's most intriguing mysteries: how the human brain learns and remembers. These studies - involving topics as diverse as musical memory, "change blindness," and attention deficit hyperactivity disorder (ADHD) - illustrate the profound influence that specific changes in either the brain's structure, function, or both, can have on human behavior.

14 Nov 2011

Cortex third quarter net loss increases to $1,175,000

Cortex Pharmaceuticals, Inc. reported a net loss of approximately $1,175,000, or $0.01 per share, for the quarter ended September 30, 2011, compared with a net loss of approximately $528,000, or $0.01 per share, for the corresponding prior year quarter.

14 Nov 2011

Damaged mitochondria equivalent to an environmental disaster in the cell

Current thinking about Parkinson's disease is that it's a disorder of mitochondria, the energy-producing organelles inside cells, causing neurons in the brain's substantia nigra to die or become impaired.

11 Nov 2011

U-M receives NIH grant for Risk Evaluation and Education for Alzheimer's Disease study

In a first-of-its kind study, University of Michigan researchers will provide genetic testing and Alzheimer's risk estimates for people who are already experiencing mild cognitive impairment.

11 Nov 2011

Delirium may increase risk of death in elderly hospital patients

Hospital patients over 65 who are referred for a psychiatric consultation and found to have delirium are more likely than those without delirium to die within one year following diagnosis, according to a new study published in the journal General Hospital Psychiatry.

11 Nov 2011

AHAF: Requests for ADR research grants increase by 33% this year

The American Health Assistance Foundation (AHAF), a nonprofit organization funding innovative research through its Alzheimer's Disease Research (ADR) program, today announced that the number of scientists seeking ADR research grants through its annual application process increased by 33% this year.

11 Nov 2011

Worm model to evaluate drugs for Parkinson's disease

Researchers at The University of Texas at Austin have devised a simple test, using dopamine-deficient worms, for identifying drugs that may help people with Parkinson's disease.

11 Nov 2011

Researchers identify how to design drugs to target specific brain areas

The future of drug design lies in developing therapies that can target specific cellular processes without causing adverse reactions in other areas of the nervous system. Scientists at the Universities of Bristol and Li-ge in Belgium have discovered how to design drugs to target specific areas of the brain.

11 Nov 2011